TScan Therapeutics, Inc. $TCRX Shares Bought by Checkpoint Capital L.P.

Key Points

• Checkpoint Capital L.P. raised its holdings in TScan Therapeutics by 14.9%, now owning 2,017,650 shares valued at approximately $2.78 million, making it the firm's 10th largest investment.
• Institutional ownership is significant, with 82.83% of TScan Therapeutics shares held by institutions and hedge funds, indicating strong support from large investors.
• Analysts have mixed outlooks on the stock, with a consensus rating of "Buy" and a price target range from $7.00 to $10.00, suggesting potential upside despite recent market volatility.

Checkpoint Capital L.P. raised its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 14.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,017,650 shares of the company's stock after acquiring an additional 261,663 shares during the quarter. TScan Therapeutics accounts for about 1.5% of Checkpoint Capital L.P.'s portfolio, making the stock its 10th biggest holding. Checkpoint Capital L.P. owned 3.57% of TScan Therapeutics worth $2,784,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of TCRX. BVF Inc. IL raised its holdings in TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock worth $6,747,000 after buying an additional 1,900,000 shares during the period. Troluce Capital Advisors LLC raised its holdings in TScan Therapeutics by 58.3% during the 1st quarter. Troluce Capital Advisors LLC now owns 83,758 shares of the company's stock worth $116,000 after buying an additional 30,844 shares during the period. Hsbc Holdings PLC acquired a new stake in TScan Therapeutics during the 1st quarter worth about $49,000. Aberdeen Group plc raised its holdings in TScan Therapeutics by 0.9% during the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after buying an additional 7,744 shares during the period. Finally, Nuveen LLC acquired a new stake in TScan Therapeutics during the 1st quarter worth about $97,000. 82.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TCRX. Wedbush reiterated an "outperform" rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. HC Wainwright dropped their target price on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Trading Up 6.9%

Shares of NASDAQ TCRX opened at $1.87 on Thursday. The stock has a market cap of $106.12 million, a price-to-earnings ratio of -1.72 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. The business has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $1.62. TScan Therapeutics, Inc. has a 52 week low of $1.02 and a 52 week high of $6.23.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.28). The firm had revenue of $3.08 million during the quarter, compared to analysts' expectations of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. On average, research analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Want to see what other hedge funds are holding TCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.